The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 2×
“Cdk2 is not essential for p21Cip1-mediated cell cycle arrest after DNA damage p21Cip1 is one of the major effectors of cell cycle arrest induced upon DNA damage (Deng et al., 1995; Brugarolas et al., 1995).”
BackgroundCheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Self-citationMouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
Luo, Y., Hurwitz, J., & Massagué, J. (1995) · Nature · doi:10.1038/375159a0 · Cited by 549
Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA
Chen, J., Jackson, P. K., Kirschner, M. W., & Dutta, A. (1995) · Nature · doi:10.1038/374386a0 · Cited by 548 · cited 2×
“For instance, p21Cip1 uses this domain to bind to the proliferating-cell nuclear antigen (PCNA), a DNA polymerase delta processivity factor, thus preventing DNA replication (Chen et al., 1995; Waga et al., 1994; Li et al., 1994; Luo et al., 1995).”
Background
Cited by
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Self-citationp21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Mammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Self-citationCdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Self-citationPyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,049
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
“On the contrary, ablation of Cdk2 in mice lacking its putative inhibitor, the p27Kip1 tumor suppressor, had no effect on tumor development (Martı́n et al., 2005).”
BackgroundSelf-citationDiril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385
Cell cycle control across the eukaryotic kingdom
Harashima, H., Dissmeyer, N., & Schnittger, A. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.03.002 · Cited by 374
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
Self-citationTargeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
Malumbres, M., & Barbacid, M. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.008 · Cited by 338
Self-citationThe Pathogenesis of Pituitary Tumors
Asa, S. L., & Ezzat, S. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092259 · Cited by 263
Cdk2 is required for p53-independent G2/M checkpoint control
Chung, J. H., & Bunz, F. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000863 · Cited by 105
Smad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
Cdc2: A monopotent or pluripotent CDK?
Hu, X., & Moscinski, L. C. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00753.x · Cited by 69
Lee, S., Kim, S., Chung, H., Moon, J. H., Kang, S. J., & Park, C.-G. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.06.006 · Cited by 57
Mitogen requirement for cell cycle progression in the absence of pocket protein activity
Foijer, F., Wolthuis, R. M. F., Doodeman, V., Medema, R. H., & te Riele, H. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.021 · Cited by 53
“This is consistent with recent work showing an inhibitory interaction of p27KIP1 and Cyclin B1 (Nakayama et al., 2004; Martin et al., 2005; Aleem et al., 2005).”
ResultDistinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production
Daszkiewicz, L., Vázquez-Mateo, C., Rackov, G., Ballesteros-Tato, A., Weber, K., Madrigal-Avilés, A., Di Pilato, M., Fotedar, A., Fotedar, R., Flores, J. M., et al. (2015) · Scientific Reports · doi:10.1038/srep07691 · Cited by 26
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Metadata
- Authors
- Martín, A., Odajima, J., Hunt, S. L., Dubus, P., Ortega, S., Malumbres, M., & Barbacid, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 7
- Issue
- 6
- Pages
- 591-598
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1994643441
- Cited by
- 223
- References
- 13
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.